Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $137,935.89 in Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 3,867 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total value of $137,935.89. Following the transaction, the insider directly owned 21,354 shares in the company, valued at approximately $761,697.18. This represents a 15.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, November 25th, Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock. The stock was sold at an average price of $54.28, for a total value of $62,801.96.

Nektar Therapeutics Stock Performance

NKTR stock opened at $37.11 on Friday. The company has a market capitalization of $754.82 million, a PE ratio of -4.66 and a beta of 1.31. Nektar Therapeutics has a one year low of $6.45 and a one year high of $66.92. The company’s 50 day moving average price is $48.45 and its two-hundred day moving average price is $44.64.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) EPS for the quarter, beating the consensus estimate of ($2.85) by $1.00. The company had revenue of $11.79 million for the quarter, compared to analyst estimates of $10.20 million. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. On average, research analysts predict that Nektar Therapeutics will post -0.72 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its position in shares of Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares during the period. FNY Investment Advisers LLC raised its stake in Nektar Therapeutics by 70.6% in the third quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,077 shares in the last quarter. Bessemer Group Inc. lifted its holdings in Nektar Therapeutics by 1,741.2% in the third quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 1,480 shares during the period. Compass Wealth Management LLC bought a new stake in Nektar Therapeutics during the 3rd quarter valued at approximately $88,000. Finally, Bayforest Capital Ltd purchased a new position in shares of Nektar Therapeutics during the 3rd quarter worth approximately $96,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Nektar Therapeutics in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. BTIG Research upped their price target on shares of Nektar Therapeutics from $100.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Jefferies Financial Group reissued a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, December 17th. Finally, HC Wainwright upped their price objective on shares of Nektar Therapeutics from $120.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $111.83.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.